• Je něco špatně v tomto záznamu ?

A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer

SA. Ohnmacht, C. Marchetti, M. Gunaratnam, RJ. Besser, SM. Haider, G. Di Vita, HL. Lowe, M. Mellinas-Gomez, S. Diocou, M. Robson, J. Šponer, B. Islam, RB. Pedley, JA. Hartley, S. Neidle,

. 2015 ; 5 (-) : 11385. [pub] 20150616

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020672

We report here that a tetra-substituted naphthalene-diimide derivative (MM41) has significant in vivo anti-tumour activity against the MIA PaCa-2 pancreatic cancer xenograft model. IV administration with a twice-weekly 15 mg/kg dose produces ca 80% tumour growth decrease in a group of tumour-bearing animals. Two animals survived tumour-free after 279 days. High levels of MM41 are rapidly transported into cell nuclei and were found to accumulate in the tumour. MM41 is a quadruplex-interactive compound which binds strongly to the quadruplexes encoded in the promoter sequences of the BCL-2 and k-RAS genes, both of which are dis-regulated in many human pancreatic cancers. Levels of BCL-2 were reduced by ca 40% in tumours from MM41-treated animals relative to controls, consistent with BCL-2 being a target for MM41. Molecular modelling suggests that MM41 binds to a BCL-2 quadruplex in a manner resembling that previously observed in co-crystal structures with human telomeric quadruplexes. This supports the concept that MM41 (and by implication other quadruplex-targeting small molecules) can bind to quadruplex-forming promoter regions in a number of genes and down-regulate their transcription. We suggest that quadruplexes within those master genes that are up-regulated drivers for particular cancers, may be selective targets for compounds such as MM41.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020672
003      
CZ-PrNML
005      
20160728115543.0
007      
ta
008      
160722s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/srep11385 $2 doi
024    7_
$a 10.1038/srep11385 $2 doi
035    __
$a (PubMed)26077929
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Ohnmacht, Stephan A $u UCL School of Pharmacy, University College London, London WC1N 1AX, UK.
245    12
$a A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer / $c SA. Ohnmacht, C. Marchetti, M. Gunaratnam, RJ. Besser, SM. Haider, G. Di Vita, HL. Lowe, M. Mellinas-Gomez, S. Diocou, M. Robson, J. Šponer, B. Islam, RB. Pedley, JA. Hartley, S. Neidle,
520    9_
$a We report here that a tetra-substituted naphthalene-diimide derivative (MM41) has significant in vivo anti-tumour activity against the MIA PaCa-2 pancreatic cancer xenograft model. IV administration with a twice-weekly 15 mg/kg dose produces ca 80% tumour growth decrease in a group of tumour-bearing animals. Two animals survived tumour-free after 279 days. High levels of MM41 are rapidly transported into cell nuclei and were found to accumulate in the tumour. MM41 is a quadruplex-interactive compound which binds strongly to the quadruplexes encoded in the promoter sequences of the BCL-2 and k-RAS genes, both of which are dis-regulated in many human pancreatic cancers. Levels of BCL-2 were reduced by ca 40% in tumours from MM41-treated animals relative to controls, consistent with BCL-2 being a target for MM41. Molecular modelling suggests that MM41 binds to a BCL-2 quadruplex in a manner resembling that previously observed in co-crystal structures with human telomeric quadruplexes. This supports the concept that MM41 (and by implication other quadruplex-targeting small molecules) can bind to quadruplex-forming promoter regions in a number of genes and down-regulate their transcription. We suggest that quadruplexes within those master genes that are up-regulated drivers for particular cancers, may be selective targets for compounds such as MM41.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x chemie $x farmakologie $7 D000970
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a G-kvadruplexy $7 D054856
650    _2
$a exprese genu $7 D015870
650    _2
$a lidé $7 D006801
650    _2
$a imidy $x chemie $x farmakologie $7 D007094
650    _2
$a injekce intravenózní $7 D007275
650    _2
$a myši $7 D051379
650    _2
$a myši nahé $7 D008819
650    _2
$a simulace molekulární dynamiky $7 D056004
650    _2
$a naftaleny $x chemie $x farmakologie $7 D009281
650    _2
$a nádory slinivky břišní $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D010190
650    12
$a promotorové oblasti (genetika) $7 D011401
650    _2
$a protoonkogenní proteiny c-bcl-2 $x antagonisté a inhibitory $x chemie $x genetika $x metabolismus $7 D019253
650    _2
$a protoonkogenní proteiny p21(ras) $x genetika $x metabolismus $7 D016283
650    _2
$a genetická transkripce $7 D014158
650    _2
$a tumor burden $x účinky léků $7 D047368
650    _2
$a xenogenní modely - testy protinádorové aktivity $7 D023041
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Marchetti, Chiara $u UCL School of Pharmacy, University College London, London WC1N 1AX, UK.
700    1_
$a Gunaratnam, Mekala $u UCL School of Pharmacy, University College London, London WC1N 1AX, UK.
700    1_
$a Besser, Rachael J $u UCL School of Pharmacy, University College London, London WC1N 1AX, UK.
700    1_
$a Haider, Shozeb M $u UCL School of Pharmacy, University College London, London WC1N 1AX, UK.
700    1_
$a Di Vita, Gloria $u UCL School of Pharmacy, University College London, London WC1N 1AX, UK.
700    1_
$a Lowe, Helen L $u UCL Cancer Institute, University College London, London WC1E 6BT, UK.
700    1_
$a Mellinas-Gomez, Maria $u UCL Cancer Institute, University College London, London WC1E 6BT, UK.
700    1_
$a Diocou, Seckou $u UCL Cancer Institute, University College London, London WC1E 6BT, UK.
700    1_
$a Robson, Mathew $u UCL Cancer Institute, University College London, London WC1E 6BT, UK.
700    1_
$a Šponer, Jiri $u 1] Central European Institute of Technology (CEITEC), Campus Bohunice, Kamenice 5, 625 00 Brno, Czech Republic [2] Institute of Biophysics, Academy of Sciences of the Czech Republic, Kralovopolska 135, 612 65, Brno, Czech Republic.
700    1_
$a Islam, Barira $u Central European Institute of Technology (CEITEC), Campus Bohunice, Kamenice 5, 625 00 Brno, Czech Republic.
700    1_
$a Pedley, R Barbara $u UCL Cancer Institute, University College London, London WC1E 6BT, UK.
700    1_
$a Hartley, John A $u UCL Cancer Institute, University College London, London WC1E 6BT, UK.
700    1_
$a Neidle, Stephen $u UCL School of Pharmacy, University College London, London WC1N 1AX, UK.
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 5, č. - (2015), s. 11385
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26077929 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160728115805 $b ABA008
999    __
$a ok $b bmc $g 1155342 $s 945200
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 5 $c - $d 11385 $e 20150616 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Možnosti archivace